Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in [...]